SNAP-tag technology: A powerful tool for site specific conjugation of therapeutic and imaging agents

Current Pharmaceutical Design

Volumn 19, Issue 30, 2013, Pages 5437-5442

  Hussain, Ahmad Fawzi ^a   Amoury, Manal ^a   Barth, Stefan ^a,b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

Antibody based therapeutic and imaging; Multifunctional nanocarrier; Photoimmunotherapy; Self labeling tag; Site specific labeling; SNAP tag

Indexed keywords

ANTIBODY; DIAGNOSTIC AGENT; GUANINE DERIVATIVE; HYBRID PROTEIN; PROTEIN; PROTEIN SNAP; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

BIOLOGY; BIOTECHNOLOGY; CANCER RESEARCH; DRUG CONJUGATION; DRUG DESIGN; DRUG LABELING; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TARGETING; MEDICINE; MOLECULAR IMAGING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; ANTIBODIES; HUMANS; MOLECULAR IMAGING; MOLECULAR PROBES; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEINS;

EID: 84881363451     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319300014     Document Type: Review

References (76)

1. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatileplatforms for cancer immunotherapy. Nature reviews Immunology 2010; 10(5): 317-27.
2. Barbet J, Chatal JF, Kraeber-Bodere F. [Radiolabeled antibodiesfor cancer treatment]. Medecine sciences: M/S 2009; 25(12): 1039-1045. Les anticorps radiomarques pour le traitement des cancers.
3. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006; 24(5): 823-34.
4. Allison RR, Sibata CH. Oncologic photodynamic therapyphotosensitizers: a clinical review. Photodiagnosis and photodynamic therapy 2010; 7(2): 61-75.
5. Hussain AF, Kampmeier F, von Felbert V, Merk HF, Tur MK, Barth S. SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells. Bioconjug Chem 2011; 22(12): 2487-95.
6. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nature medicine 2011; 17(12): 1685-91.
7. Hauser PV, Pippin JW, Kaiser C, et al. Novel siRNA deliverysystem to target podocytes in vivo. PLoS ONE 2010; 5(3): e9463.
8. Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo deliveryof small interfering RNAs via cell-surface receptors. Nature Biotechnology 2005; 23(6): 709-17.
9. Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaia N. Thenext generation of antibody-drug conjugates comes of age. Discovery medicine 2010; 10(53): 329-39.
10. Doronina SO, Toki BE, Torgov MY, et al. Development of potentmonoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21(7): 778-84.
11. Smith LM, Nesterova A, Alley SC, Torgov MY, Carter PJ. Potentcytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Molecular cancer therapeutics 2006; 5(6): 1474-82.
12. Li YM, Hall WA. Targeted toxins in brain tumor therapy. Toxins 2010; 2(11): 2645-62.
13. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxintreatment of cancer. Annual Rev Med 2007; 58: 221-37.
14. Schlick TL, Ding Z, Kovacs EW, Francis MB. Dual-SurfaceModification of the Tobacco Mosaic Virus. J Am Chem Soc 2005; 127(11): 3718-23.
15. Chen G, Heim A, Riether D, et al. Reactivity of Functional Groupson the Protein Surface: Development of Epoxide Probes for Protein Labeling. J Am Chem Soc 2003; 125(27): 8130-3.
16. Baslé E, Joubert N, Pucheault M. Protein Chemical Modificationon Endogenous Amino Acids. Chemistry & Biology 2010; 17(3): 213-27.
17. Hooker JM, Kovacs EW, Francis MB. Interior SurfaceModification of Bacteriophage MS2. Journal of the American Chemical Society 2004; 126(12): 3718-9.
18. Marks KM, Nolan GP. Chemical labeling strategies for cellbiology. Nat Meth 2006; 3(8): 591-6.
19. Kent SBH. Total chemical synthesis of proteins. Chem Soc Rev 2009; 38(2): 338-51.
20. Algar WR, Prasuhn DE, Stewart MH, et al. The controlled displayof biomolecules on nanoparticles: a challenge suited to bioorthogonal chemistry. Bioconjug Chem 2011; 22(5): 825-58.
21. Bullous AJ, Alonso CM, Boyle RW. Photosensitiser-antibodyconjugates for photodynamic therapy. Photochemical & photobiological sciences: Official J Eur Photochem Association Eur Soc Photobiol 2011; 10(5): 721-50.
22. Jeger S, Zimmermann K, Blanc A, et al. Site-specific andstoichiometric modification of antibodies by bacterial transglutaminase. Angewandte Chemie (International ed in English) 2010; 49(51): 9995-7.
23. Wang L, Amphlett G, Blattler WA, Lambert JM, Zhang W.Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein science: a publication of the Protein Society 2005; 14(9): 2436-46.
24. van Dongen GA, Visser GW, Vrouenraets MB. Photosensitizer-antibody conjugates for detection and therapy of cancer. Adv Drug Delivery Rev 2004; 56(1): 31-52.
25. Keppler A, Gendreizig S, Gronemeyer T, Pick H, Vogel H, Johnsson K. A general method for the covalent labeling of fusionproteins with small molecules in vivo. Nat Biotechnol 2003; 21(1): 86-9.
26. Gautier A, Juillerat A, Heinis C, et al. An engineered protein tagfor multiprotein labeling in living cells. Chem Biol 2008; 15(2): 128-36.
27. Los GV, Encell LP, McDougall MG, Hartzell DD, Karassina N, Zimprich C, et al. HaloTag: a novel protein labeling technology for cell imaging and protein analysis. ACS Chem Biol 2008; 3(6): 373-82.
28. Nelson AL, Reichert JM. Development trends for therapeuticantibody fragments. Nat Biotechnol 2009; 27(4): 331-7.
29. Reichert JM. Metrics for antibody therapeutics development. mAbs 2010; 2(6): 695-700.
30. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeuticnanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14(5): 1310-6.
31. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxicpayloads to monoclonal antibodies. Bioconjug Chem 2010; 21(1): 5-13.
32. Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo deliveryof small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005; 23(6): 709-17.
33. Hinner MJ, Johnsson K. How to obtain labeled proteins and whatto do with them. Current opinion in biotechnology 2010; 21(6): 766-76.
34. Meisner NC, Hintersteiner M, Seifert JM, et al. Terminal adenosyltransferase activity of posttranscriptional regulator HuR revealed by confocal on-bead screening. J Mol Biol 2009; 386(2): 435-50. Epub 2008/12/27.
35. Soh N. Selective Chemical Labeling of Proteins with SmallFluorescent Molecules Based on Metal-Chelation Methodology. Sensors 2008; 8(2): 1004-24.
36. Crivat G, Taraska JW. Imaging proteins inside cells withfluorescent tags. Trends in biotechnology 2012; 30(1): 8-16.
37. Griffin BA, Adams SR, Tsien RY. Specific covalent labeling ofrecombinant protein molecules inside live cells. Science (New York, NY) 1998; 281(5374): 269-72.
38. Machleidt T, Robers M, Hanson G. Protein Labeling With FlAsHand ReAsH. In: Taylor DL, Haskins J, Giuliano K, editors. High Content Screening: Humana Press; 2006. p 209-20.
39. Tsukiji S, Miyagawa M, Takaoka Y, Tamura T, Hamachi I. Ligand-directed tosyl chemistry for protein labeling in vivo. Nat Chem Biol 2009; 5(5): 341-3.
40. Uchinomiya SH, Nonaka H, Fujishima SH, Tsukiji S, Ojida A, Hamachi I. Site-specific covalent labeling of His-tag fused proteins with a reactive Ni(II)-NTA probe. Chemical communications (Cambridge, England) 2009(39): 5880-2.
41. Khan F, Legler PM, Mease RM, Duncan EH, Bergmann-Leitner ES, Angov E. Histidine affinity tags affect MSP1(42) structural stability and immunodominance in mice. Biotechnol J 2012; 7(1): 133-47.
42. Frese M-A, Dierks T. Formylglycine Aldehyde Tag-ProteinEngineering through a Novel Post-translational Modification. Chembiochem: a Eur J Chem Biol 2009; 10(3): 425-7.
43. Shute TS, Matsushita M, Dickerson TJ, La Clair JJ, Janda KD, Burkart MD. A Site-Specific Bifunctional Protein Labeling System for Affinity and Fluorescent Analysis. Bioconjugate Chem 2005; 16(6): 1352-5.
44. Kovalenko E, Ranjbar S, Jasenosky L, Goldfeld A, Vorobjev I, Barteneva N. The use of HaloTag-based technology in flow and laser scanning cytometry analysis of live and fixed cells. BMC Res Notes 2011; 4(1): 340.
45. Takemoto K, Matsuda T, McDougall M, et al. Chromophore-Assisted Light Inactivation of HaloTag Fusion Proteins Labeled with Eosin in Living Cells. ACS Chem Biol 2011; 6(5): 401-6.
46. Griffin BA, Adams SR, Tsien RY. Specific Covalent Labeling ofRecombinant Protein Molecules Inside Live Cells. Science (New York, NY) 1998; 281(5374): 269-72.
47. Gronemeyer T, Chidley C, Juillerat A, Heinis C, Johnsson K. Directed evolution of O6-alkylguanine-DNA alkyltransferase for applications in protein labeling. Protein engineering, design & selection: PEDS 2006; 19(7): 309-16.
48. Gronemeyer T, Godin G, Johnsson K. Adding value to fusionproteins through covalent labelling. CurrOpinion Biotechnol 2005; 16(4): 453-8.
49. Juillerat A, Gronemeyer T, Keppler A, et al. Directed evolution ofO6-alkylguanine-DNA alkyltransferase for efficient labeling of fusion proteins with small molecules in vivo. Chem Biol 2003; 10(4): 313-7.
50. Harding FA, Stickler MM, Razo J, DuBridge RB. Theimmunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. mAbs 2010; 2(3): 256-65.
51. Koyama Y, Hama Y, Urano Y, Nguyen DM, Choyke PL, Kobayashi H. Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res 2007; 13(10): 2936-45.
52. Withrow KP, Gleysteen JP, Safavy A, et al. Assessment ofindocyanine green-labeled cetuximab to detect xenografted head and neck cancer cell lines. Otolaryngology--head and neck surgery: official J Am Academy Otolaryngology-Head Neck Surgery 2007; 137(5): 729-34.
53. Alvarez-Curto E, Ward RJ, Pediani JD, Milligan G. Ligandregulation of the quaternary organization of cell surface M3 muscarinic acetylcholine receptors analyzed by fluorescence resonance energy transfer (FRET) imaging and homogeneous time resolved FRET. J Biol Chem 2010; 285(30): 23318-30.
54. Kufer SK, Dietz H, Albrecht C, et al. Covalent immobilization ofrecombinant fusion proteins with hAGT for single molecule force spectroscopy. European biophysics journal: EBJ 2005; 35(1): 72-8.
55. Sielaff I, Arnold A, Godin G, Tugulu S, Klok HA, Johnsson K.Protein function microarrays based on self-immobilizing and selflabeling fusion proteins. Chembiochem: a Eur J Chem Biol 2006; 7(1): 194-202.
56. Kampmeier F, Niesen J, Koers A, et al. Rapid optical imaging ofEGF receptor expression with a single-chain antibody SNAP-tag fusion protein. European journal of nuclear medicine and molecular imaging 2010; 37(10): 1926-34.
57. Hussain AF, Krüger HR, Kampmeier F, et al. Targeted delivery ofdendritic polyglycerol-doxorubicin conjugates by scFv-SNAP fusion protein suppresses EGFR+ cancer cell growth Submitted to Biomacromolecules.
58. Kampmeier F, Ribbert M, Nachreiner T, et al. Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferase. Bioconjug Chem 2009; 20(5): 1010-5.
59. Petershans A, Wedlich D, Fruk L. Bioconjugation of CdSe/ZnSnanoparticles with SNAP tagged proteins. Chemical communications (Cambridge, England) 2011; 47(38): 10671-3.
60. Palumbo G. Photodynamic therapy and cancer: a brief sightseeingtour. Expert Opin Drug Deliv 2007; 4(2): 131-48.
61. Alonso CM, Palumbo A, Bullous AJ, Pretto F, Neri D, Boyle RW.Site-specific and stoichiometric conjugation of cationic porphyrins to antiangiogenic monoclonal antibodies. Bioconjug Chem 2010; 21(2): 302-13.
62. Huang Z. A review of progress in clinical photodynamic therapy. Technology in cancer research & treatment 2005; 4(3): 283-93.
63. Schweitzer VG, Somers ML. PHOTOFRIN-mediatedphotodynamic therapy for treatment of early stage (Tis-T2N0M0) SqCCa of oral cavity and oropharynx. Lasers in surgery and medicine 2010; 42(1): 1-8.
64. Prise KM, O'Sullivan JM. Radiation-induced bystander signallingin cancer therapy. Nat Rev Cancer 2009; 9(5): 351-60.
65. Colombo M, Mazzucchelli S, Montenegro JM, et al. Proteinoriented ligation on nanoparticles exploiting O6-alkylguanine DNA transferase (SNAP) genetically encoded fusion. Small (Weinheim an der Bergstrasse, Germany) 2012; 8(10): 1492-7.
66. Dubowchik GM, Mosure K, Knipe JO, Firestone RA. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett 1998; 8(23): 3347-52.
67. Hamann PR, Hinman LM, Beyer CF, et al. An anti-CD33antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 2002; 13(1): 40-6.
68. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibodycytotoxic drug conjugate. Cancer Res 2008; 68(22): 9280-9290. Epub 2008/11/18.
69. Chari RV. Targeted cancer therapy: conferring specificity tocytotoxic drugs. Acc Chem Res 2008; 41(1): 98-107.
70. Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol 2000; 18(11): 2282-92.
71. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamictherapy. Journal of the National Cancer Institute 1998; 90(12): 889-905.
72. Bull Phelps SL, Schorge JO, Peyton MJ, et al. Implications ofEGFR inhibition in ovarian cancer cell proliferation. Gynecologic oncology 2008; 109(3): 411-7.
73. Fontanini G, Vignati S, Bigini D, et al. Epidermal growth factorreceptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. European journal of cancer (Oxford, England: 1990) 1995; 31A(2): 178-83.
74. Bloomston M, Bhardwaj A, Ellison EC, Frankel WL. Epidermalgrowth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Digestive Surgery 2006; 23(1-2): 74-9.
75. Calderon M, Welker P, Licha K, et al. Development of efficientacid cleavable multifunctional prodrugs derived from dendritic polyglycerol with a poly(ethylene glycol) shell. J controlled release: J Controlled Release Soc 2011; 151(3): 295-301.
76. Cole NB, Donaldson JG. Releasable SNAP-tag probes for studyingendocytosis and recycling. ACS Chem Biol 2012; 7(3): 464-9.